{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T01:59:22Z","timestamp":1793239162542,"version":"4.5.0"},"reference-count":75,"publisher":"American Society for Clinical Investigation","issue":"16","license":[{"start":{"date-parts":[[2019,8,22]],"date-time":"2019-08-22T00:00:00Z","timestamp":1566432000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"crossref","award":["Intramural funds"],"award-info":[{"award-number":["Intramural funds"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"crossref","award":["F31 AI122592"],"award-info":[{"award-number":["F31 AI122592"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"crossref"}]},{"name":"National Science Foundation","award":["GRFP 2015214731"],"award-info":[{"award-number":["GRFP 2015214731"]}]},{"DOI":"10.13039\/100021080","name":"CJD Foundation","doi-asserted-by":"crossref","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100021080","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Prion Alliance","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"DOI":"10.13039\/100013114","name":"Broad Institute","doi-asserted-by":"crossref","award":["Next Gen Fund"],"award-info":[{"award-number":["Next Gen Fund"]}],"id":[{"id":"10.13039\/100013114","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100013114","name":"Broad Institute","doi-asserted-by":"crossref","award":["BroadIgnite"],"award-info":[{"award-number":["BroadIgnite"]}],"id":[{"id":"10.13039\/100013114","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,8,22]]},"abstract":"<jats:p>\n                    Prion disease is a fatal, incurable neurodegenerative disease of humans and other mammals caused by conversion of cellular prion protein (PrP\n                    <jats:sup>C<\/jats:sup>\n                    ) into a self-propagating neurotoxic conformer (prions; PrP\n                    <jats:sup>Sc<\/jats:sup>\n                    ). Strong genetic proofs of concept support lowering PrP expression as a therapeutic strategy. Antisense oligonucleotides (ASOs) can provide a practical route to lowering 1 target mRNA in the brain, but their development for prion disease has been hindered by 3 unresolved issues from prior work: uncertainty about mechanism of action, unclear potential for efficacy against established prion infection, and poor tolerability of drug delivery by osmotic pumps. Here, we test ASOs delivered by bolus intracerebroventricular injection to intracerebrally prion-infected WT mice. Prophylactic treatments given every 2\u20133 months extended survival times 61%\u201398%, and a single injection at 120 days after infection, near the onset of clinical signs, extended survival 55% (87 days). In contrast, a nontargeting control ASO was ineffective. Thus, PrP lowering is the mechanism of action of ASOs effective against prion disease in vivo, and infrequent \u2014 or even single \u2014 bolus injections of ASOs can slow prion neuropathogenesis and markedly extend survival, even when initiated near clinical signs. These findings should empower development of PrP-lowering therapy for prion disease.\n                  <\/jats:p>","DOI":"10.1172\/jci.insight.131175","type":"journal-article","created":{"date-parts":[[2019,7,30]],"date-time":"2019-07-30T12:00:31Z","timestamp":1564488031000},"source":"Crossref","is-referenced-by-count":138,"title":["Antisense oligonucleotides extend survival of prion-infected mice"],"prefix":"10.1172","volume":"4","author":[{"given":"Gregory J.","family":"Raymond","sequence":"first","affiliation":[{"name":"Laboratory of Persistent Viral Diseases, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, NIH, Hamilton, Montana, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hien Tran","family":"Zhao","sequence":"additional","affiliation":[{"name":"Ionis Pharmaceuticals Inc., Carlsbad, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brent","family":"Race","sequence":"additional","affiliation":[{"name":"Laboratory of Persistent Viral Diseases, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, NIH, Hamilton, Montana, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynne D.","family":"Raymond","sequence":"additional","affiliation":[{"name":"Laboratory of Persistent Viral Diseases, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, NIH, Hamilton, Montana, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Williams","sequence":"additional","affiliation":[{"name":"Laboratory of Persistent Viral Diseases, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, NIH, Hamilton, Montana, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6430-6576","authenticated-orcid":true,"given":"Eric E.","family":"Swayze","sequence":"additional","affiliation":[{"name":"Ionis Pharmaceuticals Inc., Carlsbad, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Graffam","sequence":"additional","affiliation":[{"name":"Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Le","sequence":"additional","affiliation":[{"name":"Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler","family":"Caron","sequence":"additional","affiliation":[{"name":"Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacquelyn","family":"Stathopoulos","sequence":"additional","affiliation":[{"name":"Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhonda","family":"O\u2019Keefe","sequence":"additional","affiliation":[{"name":"Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori L.","family":"Lubke","sequence":"additional","affiliation":[{"name":"Laboratory of Persistent Viral Diseases, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, NIH, Hamilton, Montana, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew G.","family":"Reidenbach","sequence":"additional","affiliation":[{"name":"Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Kraus","sequence":"additional","affiliation":[{"name":"Laboratory of Persistent Viral Diseases, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, NIH, Hamilton, Montana, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart L.","family":"Schreiber","sequence":"additional","affiliation":[{"name":"Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curt","family":"Mazur","sequence":"additional","affiliation":[{"name":"Ionis Pharmaceuticals Inc., Carlsbad, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah E.","family":"Cabin","sequence":"additional","affiliation":[{"name":"McLaughlin Research Institute, Great Falls, Montana, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1711-8868","authenticated-orcid":true,"given":"Jeffrey B.","family":"Carroll","sequence":"additional","affiliation":[{"name":"Western Washington University, Bellingham, Washington, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2206-1608","authenticated-orcid":true,"given":"Eric Vallabh","family":"Minikel","sequence":"additional","affiliation":[{"name":"Laboratory of Persistent Viral Diseases, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, NIH, Hamilton, Montana, USA."},{"name":"Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA."},{"name":"Program in Biological and Biomedical Sciences, Harvard Medical School, Boston, Massachusetts, USA."},{"name":"Prion Alliance, Cambridge, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"Kordasiewicz","sequence":"additional","affiliation":[{"name":"Ionis Pharmaceuticals Inc., Carlsbad, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3928-6101","authenticated-orcid":true,"given":"Byron","family":"Caughey","sequence":"additional","affiliation":[{"name":"Laboratory of Persistent Viral Diseases, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, NIH, Hamilton, Montana, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3824-2702","authenticated-orcid":true,"given":"Sonia M.","family":"Vallabh","sequence":"additional","affiliation":[{"name":"Laboratory of Persistent Viral Diseases, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, NIH, Hamilton, Montana, USA."},{"name":"Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA."},{"name":"Program in Biological and Biomedical Sciences, Harvard Medical School, Boston, Massachusetts, USA."},{"name":"Prion Alliance, Cambridge, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"232","published-online":{"date-parts":[[2019,8,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.23.13363"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(93)90360-3"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1126\/science.1090187"},{"issue":"Pt 10","key":"B4","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1099\/vir.0.80947-0","article-title":"Prion clearance in bigenic mice","volume":"86","author":"Safar","year":"2005","journal-title":"J Gen Virol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1996.tb00467.x"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/BF03403528"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-016-1585-6"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/356577a0"},{"key":"B9","doi-asserted-by":"crossref","DOI":"10.1186\/1297-9716-43-87","article-title":"Healthy goats naturally devoid of prion protein","volume":"43","author":"Benestad","year":"2012","journal-title":"Vet Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1271"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aad5169"},{"key":"B12","doi-asserted-by":"crossref","unstructured":"Minikel EV, et al. Evaluating potential drug targets through human loss-of-function genetic variation [preprint]. doi: https:\/\/doi.org\/10.1101\/530881 Posted on bioRxiv January 28, 2019","DOI":"10.1101\/530881"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/nn.2483"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/nature19312"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0802759105"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0098496"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0011085"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0088797"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2014.01.001"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1172\/JCI25424"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2011.201"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2012.05.009"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aag0481"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2016.04.006"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/nature22044"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1172\/JCI99081"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aar3959"},{"issue":"21","key":"B28","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.123193","article-title":"Antisense oligonucleotide-mediated ataxin-1 reduction prolongs survival in SCA1 mice and reveals disease-associated transcriptome profiles","volume":"3","author":"Friedrich","year":"2018","journal-title":"JCI Insight"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1900907"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1021\/cr00102a001"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pharmtox-010716-104846"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M311683200"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkw350"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.06.002"},{"key":"B35","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2011.6","article-title":"Intracerebral Infusion of Antisense Oligonucleotides Into Prion-infected Mice","volume":"1","author":"Nazor Friberg","year":"2012","journal-title":"Mol Ther Nucleic Acids"},{"issue":"3\u20134","key":"B36","doi-asserted-by":"crossref","first-page":"190","DOI":"10.2119\/2006-00073.Karpuj","article-title":"Phosphorothioate oligonucleotides reduce PrP levels and prion infectivity in cultured cells","volume":"13","author":"Karpuj","year":"2007","journal-title":"Mol Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.3.1034-1044.2006"},{"issue":"4","key":"B38","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1128\/jvi.68.4.2135-2141.1994","article-title":"Binding of the protease-sensitive form of PrP (prion protein) to sulfated glycosaminoglycan and congo red [corrected]","volume":"68","author":"Caughey","year":"1994","journal-title":"J Virol"},{"key":"B39","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1042\/bj3420605","article-title":"Characterization and polyanion-binding properties of purified recombinant prion protein","volume":"342 Pt 3","author":"Brimacombe","year":"1999","journal-title":"Biochem J"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.3779"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1901947116"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.78.10.4999-5006.2004"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01563-07"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-013-1114-9"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.115.224659"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002445"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31408-8"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1702752"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(13)70061-9"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.113.212407"},{"key":"B51","doi-asserted-by":"crossref","unstructured":"Minikel EV, et al. Domain-specific quantification of prion protein in cerebrospinal fluid by targeted mass spectrometry [preprint]. doi: https:\/\/doi.org\/10.1101\/591487 Posted on bioRxiv April 1, 2019","DOI":"10.1101\/591487"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/nature01457"},{"key":"B53","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms5347","article-title":"Prion neuropathology follows the accumulation of alternate prion protein isoforms after infective titre has peaked","volume":"5","author":"Sandberg","year":"2014","journal-title":"Nat Commun"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0610779104"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2007.01.005"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1317164110"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.113.205799"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.116.235556"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007745"},{"key":"B60"},{"issue":"Pt 10","key":"B61","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1093\/brain\/awh249","article-title":"Predictors of survival in sporadic Creutzfeldt-Jakob disease and other human transmissible spongiform encephalopathies","volume":"127","author":"Pocchiari","year":"2004","journal-title":"Brain"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1001\/2013.jamaneurol.79"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-132465"},{"issue":"1","key":"B64","doi-asserted-by":"crossref","first-page":"e02451","DOI":"10.1128\/mBio.02451-14","article-title":"Rapid and sensitive RT-QuIC detection of human Creutzfeldt-Jakob disease using cerebrospinal fluid","volume":"6","author":"Orr\u00fa","year":"2015","journal-title":"MBio"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.378"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-10922-w"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24833"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2017.08.002"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/146.5.657"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(87)90134-6"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1021\/jo902560f"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1038\/nature08289"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1002\/prot.1077"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00865-07"},{"issue":"5","key":"B75","doi-asserted-by":"crossref","DOI":"10.3390\/v8050140","article-title":"Factors That Improve RT-QuIC Detection of Prion Seeding Activity","volume":"8","author":"Orr\u00fa","year":"2016","journal-title":"Viruses"}],"container-title":["JCI Insight"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/insight.jci.org\/articles\/view\/131175\/files\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T12:26:03Z","timestamp":1779193563000},"score":1,"resource":{"primary":{"URL":"https:\/\/insight.jci.org\/articles\/view\/131175"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,22]]},"references-count":75,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2019,8,22]]},"published-print":{"date-parts":[[2019,8,22]]}},"alternative-id":["10.1172\/jci.insight.131175"],"URL":"https:\/\/doi.org\/10.1172\/jci.insight.131175","relation":{},"ISSN":["2379-3708"],"issn-type":[{"value":"2379-3708","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,22]]},"article-number":"e131175"}}